J7353 HCPCS Reimbursement & Policy Benchmarks

HCPCS Level II code J7353 denotes Anacaulase-bcdb, an 8.8% gel supplied as 1 gram, used as a topical enzymatic agent for wound management. Nationally, clear identification of such drug-specific HCPCS codes matters for facility billing, pharmacy dispensing, and coverage determination for outpatient wound-care therapies. Accurate coding supports appropriate payment, utilization monitoring, and access to specialty topical agents.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of the code’s clinical role and typical sites of service, plus benchmarking and coverage considerations where available. The publication outlines common billing modifiers in use, highlights policy and reimbursement contexts that affect outpatient facility and pharmacy claims, and provides practical coding references for clinicians and billing staff.

This summary serves national stakeholders—providers, coders, and payers—seeking a focused briefing on the clinical purpose of J7353, the payer landscape, and the billing contexts in which the code is used. Data not available in the input are noted where applicable.

Billing Code Overview

HCPCS Level II code J7353 describes Anacaulase-bcdb, 8.8% gel, 1 gram. This entry represents a topical enzymatic gel formulation intended for debridement or enzymatic processing of wounds or related dermatologic indications, as implied by the product description.

Service type: Topical enzymatic wound-care medication
Typical site of service: Outpatient clinic, wound care center, ambulatory surgery center, or other outpatient settings where topical wound therapies are administered

Data not available in the input.

Clinical Context

A typical patient is an adult presenting to an outpatient dermatology or wound care clinic with a chronic, non-healing cutaneous lesion, postoperative wound dehiscence, or hypertrophic scar where enzymatic debridement is indicated. The clinician evaluates the wound, documents size, depth, signs of infection, and previous treatments. After informing the patient and obtaining consent, the provider prepares the wound bed, applies J7353 (Anacaulase-bcdb, 8.8% gel, 1 gram) per manufacturer instructions to enzymatically debride necrotic tissue or fibrinous slough. The application may be performed in the clinic procedure room under local anesthesia or topical analgesia; the site is dressed and wound care instructions provided. Follow-up visits are scheduled for reassessment, repeat application if needed, and documentation of wound progress, measurements, and any adverse events. Typical sites of service include outpatient dermatology clinics, wound care centers, and ambulatory surgical centers. Typical patients include those with chronic venous stasis ulcers, diabetic foot ulcers with nonviable tissue (without deep infection), pressure ulcers with slough, or postoperative wounds with localized necrosis where selective enzymatic debridement is preferred over surgical debridement.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting	Use for routine single-service reporting when no additional modifier applies.

Taxonomy Code	Specialty	Notes
`207N00000X`	Dermatology	Dermatologists commonly apply enzymatic debriding agents for chronic skin ulcers and necrotic cutaneous lesions.
`2080P0006X`	General Surgery	General surgeons manage complex wounds, postoperative necrosis, and may use enzymatic debridement in clinic settings.
`3336C0002X`	Wound Care and Hyperbaric Medicine	Wound care specialists frequently manage chronic ulcers and perform serial debridement with topical agents.
`208M00000X`	Family Medicine	Family physicians in outpatient clinics may apply enzymatic agents during wound care visits.
`207L00000X`	Plastic Surgery	Plastic surgeons involved in reconstructive or complex wound management may use enzymatic debridement as adjunct therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L97.421`	Non-pressure chronic ulcer of left heel and midfoot with fat layer exposed	Chronic lower-extremity ulcers with slough or necrosis where enzymatic debridement may be applied.
`L97.324`	Non-pressure chronic ulcer of left ankle with fat layer exposed	Common site for venous/arterial ulcers managed with selective debridement.
`L89.154`	Pressure ulcer of sacral region, stage 4	Advanced pressure injuries with necrotic tissue where enzymatic agents can assist selective debridement when appropriate.
`E11.621`	Type 2 diabetes mellitus with foot ulcer	Diabetic foot ulcers frequently require serial debridement and topical enzymatic agents are an option for non-infected necrotic tissue.
`T81.31XA`	Disruption of external operation (wound)	Postoperative wound dehiscence or localized necrosis where enzymatic debridement is used to prepare the wound bed for healing or closure.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M level for assessment, consent, and application of `J7353` in the clinic.
`97597`	Debridement, open wound, selective debridement, without anesthesia (first 20 sq cm)	May be billed when selective mechanical/enzyme-assisted debridement is performed and documentation supports coding; used for partial-thickness necrotic tissue removal.
`97598`	Each additional 20 sq cm (list separately in addition to code for primary debridement)	Use when total debridement area exceeds first 20 sq cm and documentation supports additive billing.
`11042`	Debridement, subcutaneous tissue (first 20 sq cm)	Surgical debridement code for deeper necrotic tissue removal; may be performed if enzymatic debridement is insufficient.
`29581`	Application of wound dressing (going to describe specific advanced dressings)	Often performed immediately after applying `J7353` to protect wound and maintain moisture balance.

OpenPayer

Summary & Overview

HCPCS J7353: Anacaulase-bcdb 8.8% Gel, Topical Wound Therapy